JAK2 V617F Mutation Status of 232 Patients Diagnosed With Chronic Myeloproliferative Neoplasms

Payzin K. B., Savasoglu K., ALACACIOĞLU İ., Ozdemirkiran F., Mutlu B. B., Bener S., ...Daha Fazla

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, cilt.14, sa.6, ss.525-533, 2014 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 14 Sayı: 6
  • Basım Tarihi: 2014
  • Doi Numarası: 10.1016/j.clml.2014.02.013
  • Dergi Adı: CLINICAL LYMPHOMA MYELOMA & LEUKEMIA
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.525-533
  • Anahtar Kelimeler: Essential thrombocythemia, JAK2 mutation, MPNs, Polycythemia vera, Primary myelofibrosis, JAK2V617F ALLELE BURDEN, ESSENTIAL THROMBOCYTHEMIA, POLYCYTHEMIA-VERA, LEUKEMIC TRANSFORMATION, JAK2(V617F) MUTATION, ACTIVATING MUTATION, MYELOID METAPLASIA, RISK, IDENTIFICATION, MYELOFIBROSIS
  • Dokuz Eylül Üniversitesi Adresli: Evet

Özet

The aim of this study was to investigate the presence of Janus kinase 2 (JAK2) V617F mutation in patients with BCR-ABL negative chronic myeloproliferative neoplasms (CMPNs) in our center. JAK2 V617F mutation frequencies in our PV and ET patients were similar to those reported previously. JAK2 V617F mutation frequency in our PMF patients was greater than in previous reports.